Dr. Sean Ekins named C.S.O. of HNF

Share

We are delighted to announce that after volunteering for HNF for the past year Dr. Sean Ekins, Ph.D, D.Sc. will officially become our CSO responsible for overseeing the TRIAD program, directing our scientific advisory board, and communicating our research initiatives to the scientific community. In addition he serves as the Principal Investigator of the clinical Global Registry for Inherited Neuropathy (GRIN).

Sean is Senior Consultant at Collaborations in Chemistry. He divides his time between consulting for rare disease foundations and companies including Jonah’s Just Begun, Hannah’s Hope Fund and Phoenix Nest. He is also CSO at Collaborative Drug Discovery working on tuberculosis drug discovery and collaborative software development.

He graduated from the University of Aberdeen; receiving his M.Sc. and Ph.D. in Clinical Pharmacology and then his D.Sc. in Science. He was a postdoctoral fellow at Lilly Research Laboratories working in drug disposition. He has worked as a senior scientist at Pfizer, Senior Computational Chemist at Lilly Research Laboratories, Associate Director of Computational Drug Discovery at Concurrent Pharmaceuticals, Inc. and Vice President of Computational Biology at GeneGo (now Thomson Reuters). Sean is Adjunct Professor, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; Adjunct Associate Professor, School of Pharmacy Department of Pharmaceutical Sciences, University of Maryland and Adjunct Professor in the Department of Pharmacology at University of Medicine and Dentistry of New Jersey – Robert Wood Johnson Medical School, Piscataway, NJ.

Sean is on the scientific advisory board for several companies and editorial boards of the Journal of Pharmacological and Toxicological Methods, Drug Discovery Today, Mutation Research Reviews, and Pharmaceutical Research. He has authored or co-authored >200 peer reviewed papers and book chapters as well as edited four books on computational applications in pharmaceutical R&D and computational toxicology. His latest co-edited book is “Collaborative Computational Technologies for Biomedical Research”. He currently serves on the scientific advisory board for Emiliem Inc., Assay Depot and the board of directors of the Pistoia Alliance. Sean co-developed the mobile apps ODDT (Open Drug Discovery Teams) and TB Mobile and has been awarded 7 NIH grants (STTR and SBIR) as Principal Investigator. His areas of interest are in vitro and computational ADME/Tox, drug repositioning for neglected and rare disease research, tuberculosis, systems biology, cheminformatics and computer-aided drug discovery.

Leave a Reply